1. Neonatal polycythemia and hyperviscosity
- Author
-
Shikha Sarkar and Ted S. Rosenkrantz
- Subjects
Organ blood flow ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Blood viscosity ,Exchange Transfusion, Whole Blood ,Infant, Newborn ,Exchange transfusion ,Hyperviscosity ,Polycythemia ,Blood Viscosity ,Infant newborn ,Pathophysiology ,Pediatrics, Perinatology and Child Health ,medicine ,Neonatal Polycythemia ,Etiology ,Humans ,Colloids ,Isotonic Solutions ,Intensive care medicine ,business - Abstract
Neonatal polycythemia and hyperviscosity are defined as a hematocritor =65% and a viscosity value2 standard deviations greater than the norm. Although polycythemia can reflect normal fetal adaptation, it has been thought to be responsible for abnormalities in the neonate. Polycythemia and hyperviscosity are associated with blood-flow changes in some organs, which alter their function. Partial exchange transfusion (PET) has been used to treat both symptomatic and asymptomatic patients. At present, no data support the use of PET in asymptomatic infants; the potential benefit in symptomatic infants depends on the symptoms. Studies of long-term neurodevelopmental status do not show any clear long-term benefits for PET. Crystalloids are as effective as colloids in PET and have the advantage of being cheaper and more readily available; also, they do not confer any risk of infection or anaphylaxis.
- Published
- 2008